2210415F13Rik Activators
Proteinase K Activators encompass a diverse array of chemical compounds that indirectly amplify the proteolytic activity of Proteinase K, guiding it to a more functionally active state through specific cellular and biochemical pathways. Compounds such as Dibutyryl-cAMP and Ionomycin exert their effects by activating secondary messenger systems; the former increases PKA activity which may enhance Proteinase K through phosphorylation-dependent mechanisms, while the latter raises intracellular calcium levels, potentially activating calcium-dependent pathways that might lead to the zymogen activation or alteration of regulatory cofactors of Proteinase K. Similarly, Phosphatidylserine and Oleic Acid may directly interact with the protein or alter membrane fluidity, respectively, both potentially leading to conformational changes that increase the protease's activity. Furthermore, molecules such as Sodium Taurocholate and Cetylpyridinium Chloride can modulate the interaction between Proteinase K and its lipid substrates, thus potentiating its catalytic efficiency, and Zinc and Calcium ions may serve as structural stabilizers or cofactors, respectively, enhancing the enzyme's stability and proteolytic function.
Chemicals categorized as 2210415F13Rik Activators are a specialized class of compounds identified for their capability to augment the expression of the 2210415F13Rik gene. The pursuit to discover these activators begins with a high-throughput screening (HTS) strategy, which entails meticulously examining vast chemical libraries for substances that can induce an increase in gene activity. This gene-specific activity is typically monitored using a reporter assay, where the 2210415F13Rik gene promoter is fused to a detectable reporter gene, such as GFP (Green Fluorescent Protein) or luciferase. Upon activation by a compound, the reporter gene's activity is heightened, resulting in an amplified detectable signal.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein acts as a tyrosine kinase inhibitor, which could reduce competitive phosphorylation, thereby potentially allowing pathways involving 2210415F13Rik to be less inhibited and more active, leading to its enhanced functional activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate engages with its receptors to modulate intracellular signaling pathways, including those that could converge on the activation of 2210415F13Rik, thus enhancing its functional role in the cell. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin disrupts calcium homeostasis by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased intracellular calcium which could activate calmodulin-dependent pathways potentially enhancing 2210415F13Rik activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which may phosphorylate and activate proteins within signaling cascades that include 2210415F13Rik, thus enhancing its cellular functions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which by inhibiting competitive signaling pathways, may indirectly enhance the signaling pathways that lead to the activation of 2210415F13Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that could potentiate the activation of 2210415F13Rik by dampening PI3K/Akt signaling, thus shifting the balance towards pathways that activate 2210415F13Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK, potentially enhancing signaling pathways that involve 2210415F13Rik by reducing competition from p38 MAPK-mediated phosphorylation events that might otherwise dominate cellular responses. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as an ionophore, selectively increasing intracellular calcium levels, which could activate calcium-dependent kinases and phosphatases that enhance the activity of 2210415F13Rik. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a broad-spectrum kinase inhibitor, may indirectly enhance the activity of 2210415F13Rik by inhibiting kinases that negatively regulate pathways involving 2210415F13Rik. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor that may promote the functional activity of 2210415F13Rik by inhibiting kinases that would typically phosphorylate proteins that compete with or suppress 2210415F13Rik activation. | ||||||